SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide the best opportunity for controlling transmission and protecting populations. Despite the impressive clinical trial results of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, James L, Moran, Gordon W, Gaya, Daniel R, Raine, Tim, Hart, Ailsa, Kennedy, Nicholas A, Lindsay, James O, MacDonald, Jonathan, Segal, Jonathan P, Sebastian, Shaji, Selinger, Christian P, Parkes, Miles, Smith, Philip J, Dhar, Anjan, Subramanian, Sreedhar, Arasaradnam, Ramesh, Lamb, Christopher A, Ahmad, Tariq, Lees, Charlie W, Dobson, Liz, Wakeman, Ruth, Iqbal, Tariq H, Arnott, Ian, Powell, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Rapid Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834976/
https://www.ncbi.nlm.nih.gov/pubmed/33508241
http://dx.doi.org/10.1016/S2468-1253(21)00024-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834976/
https://www.ncbi.nlm.nih.gov/pubmed/33508241
http://dx.doi.org/10.1016/S2468-1253(21)00024-8

Ejemplares similares